Wan Tai Biotech (603392.SH): Application for clinical trial of recombinant trivalent rotavirus subunit vaccine (Escherichia coli) accepted.

Chinastocks App News, Wantai Biological (603392.SH) announced that recently, its wholly-owned subsidiary Xiamen Wantai Canghai Biological Technology Co., Ltd. received an administrative license document "Acceptance Notice" from the National Medical Products Administration. The company's application for clinical trials of the "recombinant trivalent rotavirus subunit vaccine (enterotoxigenic Escherichia coli)" has been accepted.